Pharmacokinetic variability of anticancer agents

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Nature Reviews. Cancer

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrc1629PMID 15928675
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacology and Pharmacokinetics

  2012cited by this paper
• Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.

  2005cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Effects of α1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-Hydroxystaurosporine

  2004cited by this paper
• Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

  2004cited by this paper
• The Induction of Cytochrome P450 3A5 (CYP3A5) in the Human Liver and Intestine Is Mediated by the Xenobiotic Sensors Pregnane X Receptor (PXR) and Constitutively Activated Receptor (CAR)*

  2004cited by this paper
• Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

  2004cited by this paper
• The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in Caucasian and African American patients with solid tumors.

  2004cited by this paper
• Pharmacogenomics of the OATP and OAT families.

  2004cited by this paper
• Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation

  2004cited by this paper
• A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement

  2004cited by this paper
• Glucuronidation and the UDP-glucuronosyltransferases in health and disease.

  2004cited by this paper
• Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.

  2004cited by this paper
• Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression.

  2004cited by this paper
• Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

  2004cited by this paper
• Enhanced Oral Bioavailability of Paclitaxel by Coadministration of the P-Glycoprotein Inhibitor KR30031

  2004cited by this paper
• Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines

  2004cited by this paper
• Potential of chemotherapy–herb interactions in adult cancer patients

  2004cited by this paper
• Role of Red Blood Cells in Pharmacokinetics of Chemotherapeutic Agents

  2003cited by this paper
• Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

  2003cited by this paper
• A population model of epirubicin pharmacokinetics and application to dosage guidelines

  2003cited by this paper
• Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.

  2003cited by this paper
• Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics

  2003cited by this paper
• Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

  2003cited by this paper
• Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy

  2003cited by this paper
• Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.

  2003cited by this paper
• Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy.

  2003cited by this paper
• Exposure‐Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice

  2003cited by this paper
• Pharmacokinetic Considerations of Oral Chemotherapy in Elderly Patients with Cancer

  2002cited by this paper
• Effects of St. John's wort on irinotecan metabolism.

  2002cited by this paper
• Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR)

  2002cited by this paper
• Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.

  2002cited by this paper
• C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

  2002cited by this paper
• Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein

  2002cited by this paper
• Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population

  2002cited by this paper
• Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

  2002cited by this paper
• Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study.

  2002cited by this paper
• Oral Chemotherapy for the Older Patient with Cancer

  2002cited by this paper
• Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8

  2002cited by this paper
• The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups

  2001cited by this paper
• Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds.

  2001cited by this paper
• Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens

  2001cited by this paper
• Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.

  2001cited by this paper
• ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.

  2001cited by this paper
• Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects

  2001cited by this paper
• The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells.

  2001cited by this paper
• Mutation of a Single Conserved Tryptophan in Multidrug Resistance Protein 1 (MRP1/ABCC1) Results in Loss of Drug Resistance and Selective Loss of Organic Anion Transport*

  2001cited by this paper
• Gazing into a crystal ball–cancer therapy in the post-genomic era

  2001cited by this paper
• Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.

  2001cited by this paper
• The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels

  2001cited by this paper
• Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study.

  2001cited by this paper
• Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

  2001cited by this paper
• Adaptive Control Methods for the Dose Individualisation of Anticancer Agents

  2000cited by this paper
• A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.

  2000cited by this paper
• Chemotherapy in the elderly: pharmacologic considerations.

  2000cited by this paper
• Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.

  2000cited by this paper
• Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

  2000cited by this paper
• Phase I and pharmacokinetic study of oral paclitaxel.

  2000cited by this paper
• The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery

  2000cited by this paper
• Pharmacokinetic/pharmacodynamic modeling in drug development.

  2000cited by this paper
• The effect of rifampin treatment on intestinal expression of human MRP transporters.

  2000cited by this paper
• St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.

  2000cited by this paper
• Characterization of human small intestinal cytochromes P-450.

  1999cited by this paper
• Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

  1999cited by this paper
• Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.

  1999cited by this paper
• Pharmacogenomics: translating functional genomics into rational therapeutics.

  1999cited by this paper
• No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins.

  1999cited by this paper
• Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

  1999cited by this paper
• Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison.

  1999cited by this paper
• Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.

  1999cited by this paper
• Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.

  1999cited by this paper
• Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.

  1999cited by this paper
• Role of red blood cells in pharmacokinetics of chemotherapeutic agents.

  1999cited by this paper
• Oral chemotherapy: rationale and future directions.

  1998cited by this paper
• Co-administration of cyclosporin enables oral therapy with paclitaxel.

  1998cited by this paper
• New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors.

  1998cited by this paper
• The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.

  1998cited by this paper
• Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

  1998cited by this paper
• Model-Based, Goal-Oriented, Individualised Drug Therapy

  1998cited by this paper
• Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate.

  1998cited by this paper
• Pharmacokinetic Optimisation of Cancer Chemotherapy

  1997cited by this paper
• Aging and pharmacology

  1997cited by this paper
• Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

  1997cited by this paper
• Age and cytochrome P450‐linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions

  1997cited by this paper
• Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice.

  1997cited by this paper
• Influence of race or ethnicity on pharmacokinetics of drugs.

  1997cited by this paper
• Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

  1997cited by this paper
• Cancer burden in the aged

  1997cited by this paper
• Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units.

  1997cited by this paper
• Pharmacology of cancer chemotherapy in the older person.

  1997cited by this paper
• Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.

  1997cited by this paper
• An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children

  1997cited by this paper
• Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.

  1997cited by this paper
• Polypharmacy in the Older Patient With Cancer.

  1997cited by this paper
• Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

  1997cited by this paper
• Polypharmacy in the Older Patient with Cancer: The plethora of medications taken by older patients with cancer increases the risk of harmful drug interactions.

  1997cited by this paper
• A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation

  1996cited by this paper
• Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

  1996cited by this paper

• Engineering chitosan-functionalized liposomes for targeted drug delivery and biomedical applications.

  2026cites this paper
• Chitosan-encapsulated lipid-based nanovesicles for therapeutic applications and tissue engineering: A Review

  2025cites this paper
• Structure-Guided Optimization and Preclinical Evaluation of 6-O-Benzylguanine-Based Pin1 Inhibitor for Hepatocellular Carcinoma Treatment.

  2025cites this paper
• Modification in Structures of Active Compounds in Anticancer Mitochondria-Targeted Therapy

  2025cites this paper
• Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward

  2025cites this paper
• A comprehensive review about the anticancer properties of gigantol.

  2025cites this paper
• Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics

  2025influential citation
• Integrated design and application of stimuli-responsive metal-organic frameworks in biomedicine: current status and future perspectives.

  2024cites this paper
• Roadmap for Clinical Translation of Mobile Microrobotics

  2024cites this paper
• Vincristine‐induced adverse events related to body weight in dogs treated for lymphoma

  2024cites this paper
• Pharmacological Activities of Plant‐Derived Fraxin with Molecular Mechanisms: A Comprehensive Review

  2024cites this paper
• Mechano-assisted strategies to improve cancer chemotherapy.

  2024cites this paper
• Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

  2023cites this paper
• Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells

  2023cites this paper
• Promising applications of nanotechnology in inhibiting chemo-resistance in solid tumors by targeting epithelial-mesenchymal transition (EMT).

  2023cites this paper
• Lipid Nanocapsule: A Novel Approach to Drug Delivery System Formulation Development.

  2023cites this paper
• Evaluation of therapeutics' drug monitoring during cancer chemotherapy: A review

  2023cites this paper
• Engineering versatile nano-bacteria hybrids for efficient tumor therapy

  2023cites this paper
• Implantable Hydrogel-Protective DNA Aptamer-Based Sensor Supports Accurate, Continuous Electrochemical Analysis of Drugs at Multiple Sites in Living Rats.

  2023cites this paper
• Synergistic Combination of Letrozole and Berberine in Ascorbic Acid-Stabilized AuNPs: A Promising Solution for Breast Cancer

  2023cites this paper
• Cisplatin and oleanolic acid Co-loaded pH-sensitive CaCO3 nanoparticles for synergistic chemotherapy

  2022cites this paper
• Evaluation of nine formulas for estimating the body surface area of children with hematological malignancies

  2022cites this paper
• Chemotherapy in Lung Cancer With Hepatic and Renal Impairment

  2022influential citation
• Galactose engineered nanocarriers: Hopes and hypes in cancer therapy

  2022cites this paper
• On the Rational Design of Cooperative Receptors

  2022cites this paper
• The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients

  2022cites this paper
• Real-Time, Seconds-Resolved Measurements of Plasma Methotrexate In Situ in the Living Body.

  2022cites this paper
• Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis

  2022cites this paper
• Modeling Drug Concentration Level in Blood Using Fractional Differential Equation Based on Psi-Caputo Derivative

  2022cites this paper
• Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study

  2022cites this paper
• A selective p53 activator and anticancer agent to improve colorectal cancer therapy.

  2021cites this paper
• De novo identification of maximally deregulated subnetworks based on multi-omics data with DeRegNet

  2021cites this paper
• Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC‐guided dosing in nonsmall cell lung cancer

  2021cites this paper
• A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors

  2021cites this paper
• Precise sample metering method by coordinated burst action of hydrophobic burst valves applied to dried blood spot collection.

  2021cites this paper
• A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.

  2021cites this paper
• Advanced mesoporous silica nanocarriers in cancer theranostics and gene editing applications.

  2021cites this paper
• Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing

  2021cites this paper
• Dose, dosage regimen, and dose adjustment in organ failure

  2021cites this paper
• High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs

  2021cites this paper
• Stimuli-responsive nano-assemblies for remotely controlled drug delivery.

  2020cites this paper
• Supportive care medications coinciding with chemotherapy among children with hematologic malignancy

  2020cites this paper
• Biodynamic signatures from ex vivo bone marrow aspirates are associated with chemotherapy‐induced neutropenia in cancer‐bearing dogs

  2020cites this paper
• Biological evaluation and pharmacokinetic profiling of a coumarin-benzothiazole hybrid as a new scaffold for human gliomas

  2020cites this paper
• Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients

  2020cites this paper
• Clinical Opportunities for Continuous Biosensing and Closed-Loop Therapies

  2020cites this paper
• Application of Pharmacometrics of 5-Fluorouracil to Personalized Medicine: A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses

  2020cites this paper
• Effect of Body Fat on Population Pharmacokinetics of High‐Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia

  2020cites this paper
• The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology

  2020cites this paper
• Hydrogel-coating improves the in-vivo stability of electrochemical aptamer-based biosensors

  2020cites this paper
• Unveiling the Impact of Morphine on Tamoxifen Metabolism in Mice in vivo

  2020cites this paper
• Cell deformation and acquired drug resistance: elucidating the major influence of drug-nanocarrier delivery systems.

  2020cites this paper
• Novel β-1,3-d-glucan porous microcapsule enveloped folate-functionalized liposomes as a Trojan horse for facilitated oral tumor-targeted co-delivery of chemotherapeutic drugs and quantum dots.

  2020cites this paper
• Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions.

  2020cites this paper
• Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring.

  2020cites this paper
• Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer.

  2020cites this paper
• 5-Fluorouracil Response Prediction and Blood Level-guided Therapy in Oncology: Existing Evidence Fundamentally Supports Instigation.

  2020cites this paper
• ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib

  2020cites this paper
• Applications and challenges in therapeutic drug monitoring of cancer treatment: A review

  2020cites this paper
• Cancer-targeted chemotherapy: Emerging role of the folate anchored dendrimer as drug delivery nanocarrier

  2020cites this paper
• Design and Analysis of a Sample-and-Hold CMOS Electrochemical Sensor for Aptamer-Based Therapeutic Drug Monitoring

  2020cites this paper
• CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

  2020influential citation
• Polytherapy and Targeted Cancer Drug Resistance.

  2019cites this paper
• The influence of external factors on the pharmacokinetics of oral targeted anticancer drugs

  2019cites this paper
• Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre

  2019cites this paper
• Mesenchymal stem cell therapies in brain disease.

  2019cites this paper
• Mathematical Analysis of a Mathematical Model of Chemovirotherapy: Effect of Drug Infusion Method

  2019cites this paper
• Therapeutic potential of withaferin A against non-small cell lung cancer.

  2019influential citation
• Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects

  2019cites this paper
• Cancer Chemotherapy

  2019cites this paper
• STUDY OF JADOMYCIN PHARMACOKINETICS AND ANTI-BREAST CANCER ACTIVITY IN BALB/C MICE

  2019cites this paper
• Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy

  2019cites this paper
• Seconds-resolved pharmacokinetic measurements of the chemotherapeutic irinotecan in situ in the living body

  2019cites this paper
• Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article.

  2019cites this paper
• [Venous thromboembolism and urological cancer: Epidemiology and therapeutically management].

  2019cites this paper
• Ultrasensitive SERS Substrate for Label-Free Therapeutic-Drug Monitoring of Paclitaxel and Cyclophosphamide in Blood Serum.

  2019cites this paper
• Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy

  2019influential citation
• Flaxseed Lignans as Important Dietary Polyphenols for Cancer Prevention and Treatment: Chemistry, Pharmacokinetics, and Molecular Targets

  2019cites this paper
• Monoclonal antibody pharmacogenomics in cancer treatment

  2019cites this paper
• Pharmacodynamic and pharmacokinetic characteristics of YMR‐65, a tubulin inhibitor, in tumor‐bearing mice

  2018cites this paper
• Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis.

  2018cites this paper
• Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer

  2018cites this paper
• Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery

  2018cites this paper
• Overcoming multiple drug resistance in cancer using polymeric micelles

  2018cites this paper
• Role of Clinical Pharmacokinetics Studies in Contemporary Oncology Drug Development

  2018cites this paper
• Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre

  2018cites this paper
• On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site

  2018cites this paper
• Drug metabolizing enzymes and their inhibitors' role in cancer resistance.

  2018cites this paper
• Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences.

  2018cites this paper
• Measuring Chemotherapy Response in Breast Cancer Using Optical and Ultrasound Spectroscopy

  2018influential citation
• Mobile Magnetic Nanocatalysts for Bioorthogonal Targeted Cancer Therapy

  2018cites this paper
• Characterizing the Sources of Pharmacokinetic Variability for TAK‐117 (Serabelisib), an Investigational Phosphoinositide 3‐Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy

  2018cites this paper
• How can we best monitor 5-FU administration to maximize benefit to risk ratio?

  2018cites this paper
• Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.

  2017cites this paper
• Drug delivery: Closed-loop dynamic dosing

  2017cites this paper
• Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance

  2017cites this paper
• The Effect of Sparkling Water on Intraluminal Formulation Behavior and Systemic Drug Performance.

  2017cites this paper
• Associations of High‐Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial

  2017cites this paper
• Evaluation of the performance of elastomeric pumps in practice: are we under-delivering on chemotherapy treatments?

  2017cites this paper
• University of Birmingham Repurposing itraconazole for the treatment of cancer

  2017cites this paper